BRISTOL-MYERS SQUIBB COMPANY Unrecognized Tax Benefits, Increase Resulting from Acquisition
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Unrecognized Tax Benefits, Increase Resulting from Acquisition of $12.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, increase resulting from acquisition for fiscal 2025 was $12.00M, a 89.38% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, increase resulting from acquisition for fiscal 2024 was $113.00M.
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, increase resulting from acquisition for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, increase resulting from acquisition for fiscal 2022 was $15.00M.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Acquisition 12 month |
|---|---|
| 2025-12-31 | $12.00M 10-K · filed 2026-02-11 |
| 2024-12-31 | $113.00M 10-K · filed 2026-02-11 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-11 |
| 2022-12-31 | $15.00M 10-K · filed 2025-02-12 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-13 |
| 2020-12-31 | $51.00M 10-K · filed 2023-02-14 |
| 2019-12-31 | $852.00M 10-K · filed 2022-02-09 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-10 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-24 |
| 2016-12-31 | $1.00M 10-K · filed 2019-02-25 |
| 2015-12-31 | $1.00M 10-K · filed 2018-02-13 |
| 2012-12-31 | $31.00M 10-K · filed 2015-02-13 |
| 2011-12-31 | $1.00M 10-K · filed 2014-02-14 |
| 2010-12-31 | $11.00M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |